Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer-The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol.
NSCLC
bronchoscopy
cryobiopsy
forceps biopsy
molecular genetic characterization
next generation sequencing
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
06 Jul 2020
06 Jul 2020
Historique:
received:
28
05
2020
revised:
22
06
2020
accepted:
24
06
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
The detection of molecular alterations is crucial for the individualized treatment of advanced non-small cell lung cancer (NSCLC). Missing targetable alterations may have a major impact on patient's progression free and overall survival. Although laboratory testing for molecular alterations has continued to improve; little is known about how biopsy technique affects the detection rate of different mutations. In the retrospective study detection rate of epidermal growth factor (EGFR) mutations in tissue extracted by bronchoscopic cryobiopsy (CB was significantly higher compared to other standard biopsy techniques. This prospective, randomized, multicenter, single blinded study evaluates the accuracy of molecular genetic characterization of NSCLC for different cell sampling techniques. Key inclusion criteria are suspected lung cancer or the suspected relapse of known NSCLC that is bronchoscopically visible. Patients will be randomized, either to have a CB or a bronchoscopic forceps biopsy (FB). If indicated, a transbronchial needle aspiration (TBNA) of suspect lymph nodes will be performed. Blood liquid biopsy will be taken before tissue biopsy. The primary endpoint is the detection rate of molecular genetic alterations in NSCLC, using CB and FB. Secondary endpoints are differences in the combined detection of molecular genetic alterations between FB and CB, TBNA and liquid biopsy. This trial plans to recruit 540 patients, with 178 evaluable patients per study cohort. A histopathological and molecular genetic evaluation will be performed by the affiliated pathology departments of the national network for genomic medicine in lung cancer (nNGM), Germany. We will compare the diagnostic value of solid tumor tissue, lymph node cells and liquid biopsy for the molecular genetic characterization of NSCLC. This reflects a real world clinical setting, with potential direct impact on both treatment and survival.
Identifiants
pubmed: 32640669
pii: diagnostics10070459
doi: 10.3390/diagnostics10070459
pmc: PMC7400559
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Astra Zeneca
ID : PROFILER Study
Références
Indian J Cancer. 2017 Jan-Mar;54(1):280-284
pubmed: 29199706
Cancer Sci. 2008 May;99(5):929-35
pubmed: 18325048
Pol J Pathol. 2018;69(3):278-284
pubmed: 30509054
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
J Clin Oncol. 2018 Aug 1;36(22):2244-2250
pubmed: 29864379
Indian J Cancer. 2017 Dec;54(Supplement):S45-S54
pubmed: 29292708
Adv Respir Med. 2017;85(6):301-306
pubmed: 29288478
J Clin Oncol. 2018 Mar 20;36(9):911-919
pubmed: 29401004
J Thorac Cardiovasc Surg. 2014 Oct;148(4):1169-77
pubmed: 24930616
Respiration. 2018;95(6):383-391
pubmed: 29894993
Oncologist. 2012;17(7):978-85
pubmed: 22673630
Thorac Cancer. 2018 Nov;9(11):1461-1469
pubmed: 30253083
Thorax. 2013 Aug;68 Suppl 1:i1-i44
pubmed: 23860341
BMC Cancer. 2019 Apr 23;19(1):369
pubmed: 31014278
Thorax. 2011 Nov;66 Suppl 3:iii1-21
pubmed: 21987439
Mol Imaging Biol. 2019 Oct;21(5):965-972
pubmed: 30478506
Transl Lung Cancer Res. 2013 Dec;2(6):445-8
pubmed: 25806267
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
PLoS One. 2015 Mar 30;10(3):e0121323
pubmed: 25822850
Am J Clin Pathol. 2015 Oct;144(4):629-34
pubmed: 26386084
Clin Lung Cancer. 2018 May;19(3):230-238.e2
pubmed: 29277564
Nat Commun. 2018 Dec 18;9(1):5361
pubmed: 30560866
J Transl Med. 2014 May 16;12:131
pubmed: 24885034
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
Ann Oncol. 2015 Sep;26(9):1877-1883
pubmed: 26141208
Lung Cancer. 2017 Apr;106:131-137
pubmed: 28285687
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
PLoS One. 2017 Oct 19;12(10):e0186192
pubmed: 29049375
Anticancer Res. 2018 Jun;38(6):3559-3566
pubmed: 29848710
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
J Bronchology Interv Pulmonol. 2019 Apr;26(2):129-131
pubmed: 30913043
Lancet Respir Med. 2015 Apr;3(4):282-9
pubmed: 25660225
Hum Pathol. 2016 May;51:139-45
pubmed: 26980023
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
Int J Cancer. 2017 Jan 1;140(1):103-108
pubmed: 27646734
Pathologe. 2019 May;40(3):276-280
pubmed: 31101971
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Respiration. 2017;94(2):216-223
pubmed: 28531883
South Med J. 2018 Aug;111(8):484-488
pubmed: 30075474
J Clin Oncol. 2014 Nov 10;32(32):3673-9
pubmed: 25311215
PLoS One. 2013 Oct 29;8(10):e77948
pubmed: 24205040
Respiration. 2008;76(2):193-7
pubmed: 18708736
Ann Oncol. 2015 Sep;26(9):1883-1889
pubmed: 26105600
Clin Lung Cancer. 2018 Jul;19(4):e421-e430
pubmed: 29609906
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
Thorac Cancer. 2018 Jul;9(7):856-864
pubmed: 29761660
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
Am J Respir Crit Care Med. 2012 Jun 15;185(12):1316-22
pubmed: 22505743
BMC Pulm Med. 2016 Jul 26;16(1):106
pubmed: 27457475
Surg Today. 2019 Jan;49(1):1-14
pubmed: 29644440
J Thorac Oncol. 2010 Jan;5(1):29-33
pubmed: 19952801
Am J Clin Pathol. 2012 Sep;138(3):332-46
pubmed: 22912349
Yonsei Med J. 2019 Jun;60(6):525-534
pubmed: 31124335
J Clin Oncol. 2013 Sep 20;31(27):3342-50
pubmed: 23816967
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Chest. 2016 Mar;149(3):816-35
pubmed: 26402427
J Thorac Oncol. 2013 Jul;8(7):823-59
pubmed: 23552377
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Eur Respir J. 2012 Mar;39(3):685-90
pubmed: 21852332
J Cancer. 2018 Mar 2;9(6):1113-1120
pubmed: 29581791
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
Lung. 2016 Jun;194(3):371-8
pubmed: 26951235
Respiration. 2014;88(6):500-17
pubmed: 25377908
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Cancer Chemother Pharmacol. 2012 May;69(5):1241-6
pubmed: 22278730
Lung Cancer. 2020 Mar;141:56-63
pubmed: 31955001
J Clin Oncol. 2011 Jul 20;29(21):2866-74
pubmed: 21670455
J Clin Pathol. 2017 Sep;70(9):798-802
pubmed: 28363898
J Thorac Oncol. 2016 Oct;11(10):1653-71
pubmed: 27364315
Cancer Res. 2015 Oct 15;75(20):4372-83
pubmed: 26282169
BMC Cancer. 2019 Jun 7;19(1):546
pubmed: 31174496